Neurodegenerative Disease
Vico Therapeutics B.V. focuses on clinical research in spinocerebellar ataxia type 1, spinocerebellar ataxia type 3, and Huntington’s disease, with attention to disorders marked by progressive motor and neurological impairment.
- Spinocerebellar ataxia type 1
- Spinocerebellar ataxia type 3
- Huntington’s disease
The sponsor’s research activity is centered on conditions affecting coordination, movement control, and neurological function.
Genetic Neurology
The clinical portfolio includes inherited neurological disorders associated with abnormal gene expression and progressive central nervous system dysfunction.
- Hereditary ataxia
- Polyglutamine disease
- Movement disorder
Research interest is directed toward diseases with shared genetic and neurodegenerative mechanisms.
Intrathecal Neurotherapeutics
Vico Therapeutics B.V. is engaged in studies of intrathecal administration for therapies delivered to the cerebrospinal fluid, reflecting a focus on direct treatment of neurological disease.
- Intrathecal delivery
- Lumbar administration
- Central nervous system targeting
This area links therapeutic development with neurological access strategies for disorders that require direct CNS exposure.
Neurological Biomarkers and Clinical Assessment
The sponsor’s trial activity includes evaluation of safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with manifest neurodegenerative disease.
- Safety assessment
- Tolerability evaluation
- Pharmacodynamic response
Clinical interest extends to measurable treatment effects in inherited neurological disorders.
